AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06155149 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile application
Description: Mobile application: The content of the mobile application that can be used continuously after the presentation in the education of families will consist of three parts.~In the first section: There will be short information notes and visuals on burn diagnosis and types.~Second part: Frequently seen burns as a result of home accidents will be introduced and the precautions to be taken will be included through visuals.~Third Section: First aid applications specific to each type of burn (scalding, fire-flame, hot contact, electrical, chemical) will be presented with visuals and information notes.
Study NCT06155149 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Family Information Training
Description: Family Information Training: The content of the training to be held for families in the form of a powerpoint presentation is as follows: definition of burns, classification of burns, common causes of burns at home, measures to prevent burns at home, first aid applications in burns.
Study NCT06155149 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family Information Training
Description: Family Information Training: The content of the training to be held for families in the form of a powerpoint presentation is as follows: definition of burns, classification of burns, common causes of burns at home, measures to prevent burns at home, first aid applications in burns.
Study NCT05531838 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Fu Lishan instant sense hospital dynamic glucose monitoring system
Description: Using CGM Technology (dynamic glucose monitoring system used in Fu Lishan instant sense hospital), on the basis of patients' original eating habits, according to the guidelines and the training of MMC center, patients are guided to adjust their eating patterns according to the glucose map monitored by the dynamic glucose monitoring system.
Study NCT05775146 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiation treatment (SBRT)
Description: SBRT uses 3D imaging to target high doses of radiation to the affected area. There is very little damage to the surrounding healthy tissue. SBRT works by damaging the DNA of the targeted cells. Then, the affected cells can't reproduce, which causes tumors to shrink.
Study NCT05951231 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Liver transplantation
Description: Patients who receive an ECD liver after an ex-vivo liver perfusion where the liver has been tested for function and approved according to international functional criteria (Groeningen criteria)
Study NCT05128487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NDI-101150
Description: NDI-101150 capsules
Study NCT04975373 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Intrauterine injection of hyaluronic acid
Description: operative hysteroscopy - as a part of treatment in cases with retained placenta after delivery diagnostic hysteroscopy - as a routine evaluation after removal of placenta
Study NCT05128487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab IV infusion
Study NCT06152341 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ATC System
Description: The ATC System is designed to mechanically remove emboli and restore blood flow through the pulmonary arteries in patients experiencing acute PE
Study NCT06435598 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: video-based health education
Description: The video- based health education program guided by the Health Belief Model will be designed to provide tailored information on insulin therapy in diabetes. Health Belief Model(HBM) emphasizes changes in people's behavior are acquired through awareness of risk factors and perceived health benefits. The video will provide general information on insulin, types of insulin, its administration technique and storage.
Study NCT05503797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plixorafenib
Description: Oral tablets
Study NCT05503797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobicistat
Description: Oral tablets
Study NCT04065386 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active taVNS
Description: Patients will receive transcutaneous auricular vagal nerve stimulation (taVNS) for 5 consecutive days, at the cymba conchae, bilaterally, during 45 minutes (alternating 30 s on and 30 s off periods). Current intensity: 3 mA or less according to the participant's pain threshold, width: 200-300 μsec.
Study NCT04065386 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham taVNS
Description: Patients will receive transcutaneous auricular vagal nerve stimulation (taVNS) for 5 consecutive days, at the ear lobe, bilaterally, during 45 minutes (alternating 30 s on and 30 s off periods). Current intensity: 3 mA or less according to the participant's pain threshold, width: 200-300 μsec.
Study NCT05224141 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab/Vibostolimab Co-Formulation
Description: Pembrolizumab 200 mg plus vibostolimab 200 mg fixed dose coformulation administered via IV infusion Q3W on Day 1 of each cycle until discontinuation criteria are met.
Study NCT05224141 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline placebo
Description: Saline solution administered via IV infusion on Cycle 1 (and Q3W as needed beyond Cycle 1)
Study NCT05224141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline placebo
Description: Saline solution administered via IV infusion on Cycle 1 (and Q3W as needed beyond Cycle 1)
Study NCT05224141 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Etoposide 100 mg/m\^2 administered via IV infusion Q3W on Days 1 2, 3 of each cycle for up to 4 cycles
Study NCT05224141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 100 mg/m\^2 administered via IV infusion Q3W on Days 1 2, 3 of each cycle for up to 4 cycles
Study NCT05224141 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 75 mg/m\^2 administered via IV infusion Q3W on Day 1 of each cycle for up to 4 cycles.
Study NCT05224141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 75 mg/m\^2 administered via IV infusion Q3W on Day 1 of each cycle for up to 4 cycles.
Study NCT05224141 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg administered via IV infusion Q3W on Day 1 of each cycle until discontinuation criteria are met.
Study NCT05224141 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin AUC 5 mg/mL/min administered via IV infusion Q3W on Day 1 of each cycle for up to 4 cycles.
Study NCT05224141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 5 mg/mL/min administered via IV infusion Q3W on Day 1 of each cycle for up to 4 cycles.
Study NCT06583538 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Giraffe Healthcare
Description: An online personalised rehabilitation platform consisting of exercise videos with written and audio instruction, an exercise diary, advice and in-built messaging system between therapist and participant.~The exercise prescription consists of strengthening, aerobic and stretching. 40mins per session, twice per week, for 12 weeks
Study NCT05246111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]Berzosertib
Description: Participants received single intravenous infusion of \[14C\]Berzosertib at a dose of 210 milligrams per square meter (mg/m\^2) on Day 1 in Period 1 and stay in clinical research unit (CRU) is required until the discharge criteria are met with a maximum confinement period of 15 days.
Study NCT05246111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berzosertib
Description: Participants received single intravenous infusion of Berzosertib at a dose of 210 mg/m\^2 on Day 2 and Day 5 in period 2 until disease progression or other criteria for study intervention discontinuation were met.
Study NCT05246111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Participants received topotecan at a dose of 1.25 mg/m\^2 intravenously on Days 1 through 5 of each 21-day cycle in period 2 until disease progression or other criteria for study intervention discontinuation were met.
Study NCT04983823 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heart Failure intervention (Cardiac COVID Disease Management Plan (CC-DMP)
Description: A clinical review to ensure optimal risk factor control and cardioprotection along with exercise intervention.
Study NCT04983823 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: This will be provided by participants' usual healthcare professional(s).
Study NCT04976335 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Versawrap membrane
Description: Versawrap membrane will be placed between distal radius plate and flexor tendons
Study NCT04323449 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compare two control methods for a wheelchair-mounted robotic manipulator
Description: Participants will pay one visit to the lab where they will be asked to complete a set of manipulation tasks using a wheelchair-mounted robotic manipulator using the new custom vision-guided control and default joystick or switch control. The sequence of the two control methods will be counterbalanced.
Study NCT06562530 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high tone power therapy
Description: sessions are applied for 30 minutes, 3 times per week, for 3 months
Study NCT06562530 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous electrical nerve stimulation (TENS)
Description: sessions are applied for 30 minutes, 3 times per week, for 3 months
Study NCT06562530 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: selected physical therapy program
Description: sessions are applied for 1 hour, 3 times per week, for 3 months in form o fstretching exercise , range of motion exercises , conventional gait training progressive resistance exercises
Study NCT06562530 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: selected physical therapy program
Description: sessions are applied for 1 hour, 3 times per week, for 3 months in form o fstretching exercise , range of motion exercises , conventional gait training progressive resistance exercises
Study NCT05515627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg administered via intravenous infusion every 3 weeks
Study NCT05855525 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experience sampling
Description: Participants will repeatedly and intermittently report the content of their ongoing, self-generated experiences based on an experience-sampling protocol in which self-report ratings will be triggered based on real-time analysis of the participant's current brain state. The protocol will be conducted while participants are undergoing MRI scanning.
Study NCT06568653 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: exosome
Description: human placenta mesenchymal stem cell-derived exosome
Study NCT06568653 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: routine conventional fistulotomy
Description: routine conventional fistulotomy
Study NCT05649852 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Socio-aesthetic care
Description: Group A (Socio-aesthetic care): 3 sessions carried out by a socio-esthetician, during the first administration of chemotherapy.
Study NCT05649852 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Supportive care
Description: Group B (control) will not benefit of socio-aesthetic care during chemotherapy but will benefit all existing support care in the center and accessible to patients: psychology consultation, sophrology, art therapy, physiotherapy, hypnosis. The patient will receive support care (maximum 2) during the intercure.
Study NCT04437082 — intervention group
Intervention type: DEVICE
Intervention: optical coherence tomography
Description: imaging structural and vascular features of the eye
Study NCT04979819 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper extremity endurance test (UULEX)
Description: Patients will lift 5 bars consecutively rhythmically until they feel fatigued. The bars will weigh 200 grs 500 gr 1kgs and 2 kgs respectively. The duration of the test will be measured to determine the endurance levels of the patients.
Study NCT05679492 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meplazumab foe injection
Description: Meplazumab is a humanized anti-CD147 immunoglobulin 2 (IgG2) monoclonal antibody which is expected to block the binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein to the human host-cell-expressed CD147, thereby blocking entry of SARS-CoV-2 into human tissue. This expectation is based on in vitro functional studies using Vero E6 cells infected with SARS-CoV-2 that demonstrated effective meplazumab mediated virus gene copy number inhibition upwards of 90% as evaluated by quantitative polymerase chain reaction. Meplazumab may also inhibit COVID-19 associated cytokine storm syndrome based on inhibition of the pro inflammatory factor Cyclophilin A host-cell CD147 interaction.
Study NCT05679492 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline
Study NCT04873375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: After inclusion patients will be treated with Cemiplimab 350mg intravenously every three weeks
Study NCT05194410 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: First 3 months of virtual, team-based exercise
Description: Participants will be randomized onto mixed teams of medical students, residents, fellows, and attendings and registered for the virtual, team-based exercise intervention on FitRankings.com. All exercise (including walking, biking, lifting, yoga, and 40+ exercises) will be tracked via user's smartwatches (ie Apple, Garmin), smartphone fitness apps (ie MapMyRun), or manual upload, converted into Metabolic Equivalent of a Task (MET) minutes, and displayed on online leaderboards. Group activities will be encouraged by awarding raffle tickets for prizes to those who submit pictures with their teammates.
Study NCT05194410 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Second 3 months of virtual, team-based exercise
Description: Same as above
Study NCT05194410 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Second 3 months of virtual, team-based exercise
Description: Same as above
Study NCT05244356 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health message exposure
Description: Participants exposed to a health message and requested to read it completely. Subsequently requested to answer post intervention questions that form basis for outcome measures.
Study NCT05027373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSGJ-613
Description: SSGJ-613 injection is 200mg/2mL solution in a single vial.The solution is a clear to slightly opalescent, colorless to a slightly yellow tint.
Study NCT05027373 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injection is 2mL excipient solution in a single vial.The solution is clear and colorless.
Study NCT05786781 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transarterial CT angiography
Description: Transarterial catheter-directed CT angiography during interventional treatment of hemoptysis
Study NCT05384197 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced regimen
Description: Sulfamethoxazole-Trimethoprim (TMP-SMX) twice daily will be utilized as the first choice AP for 2 days with the last day of AP course being one day prior to intervention.~In patients with allergy or resistance to TMP-SMX, the following antibiotics will be considered in the following order: 100 mg Nitrofurantoin twice daily, 500 mg Ciprofloxacin twice daily or 200 mg Cefpodoxime twice daily.~Patients with positive culture which is sensitive only to parenteral antibiotics will receive culture-based intramuscular/intravenous antibiotics following the same schedule (2 days with the last day of AP course being one day prior to intervention)
Study NCT05384197 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Extended regimen
Description: Sulfamethoxazole-Trimethoprim (TMP-SMX) twice daily will be utilized as the first choice AP for 7 days with the last day of AP course being one day prior to intervention.~In patients with allergy or resistance to TMP-SMX, the following antibiotics will be considered in the following order: 100 mg Nitrofurantoin twice daily, 500 mg Ciprofloxacin twice daily or 200 mg Cefpodoxime twice daily.~Patients with positive culture which is sensitive only to parenteral antibiotics will receive culture-based intramuscular/intravenous antibiotics following the same schedule (7 days with the last day of AP course being one day prior to intervention)
Study NCT06416007 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Lattice therapy (LRT)
Description: 5 Fractions LRT
Study NCT03806478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APH-1105
Description: The investigational drug product, APH-1105 is a sterile, pyrogen-free lyophilized powder intended for intranasal administration.
Study NCT03806478 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is a sterile, pyrogen free lyophilized powder identical in appearance to the experimental drug
Study NCT06349434 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyoMo
Description: To evaluate the usefulness of extended utilization of an upper extremity assistive device, called (MyoPro) in improving upper extremity (UE) activities in people with spinal cord injury (SCI).
Study NCT06349434 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy
Description: To evaluate the usefulness of extended conventional therapy compared to the utilization of an upper extremity assistive device called (MyoPro) in improving upper extremity (UE) activities in people with spinal cord injury.
Study NCT06418360 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TECAR
Description: Transfer Energy Capacitative and Resistive Therapy
Study NCT06464835 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation
Description: The treatment parameter for iTBS was 80% stimulus intensity. The stimulation frequency was 50Hz in the plexus and 5Hz in the interplexus. Each burst stimulus consisted of 3 consecutive pulses, 2s stimulus, 8s interval, and repeated 20 times, a total of 600 pulses, and the duration of stimulation was 189s. NMES treatment parameters for output waveform for two-way square wave, wave width 700 ms, positive and negative half wave (300 ms) between 100 ms intermittent, stimulating frequency 50 hz, treatment when the output intensity range of 0 \~ 25 ma, stimulating electrodes pasted in bilateral mandibular hyoid muscle movement points, output intensity in patients with tongue bone muscle group it is advisable to have a sense of fashion, extrusion. Each treatment lasted 30 minutes, once a day, 5 times a week for 2 weeks.
Study NCT06632041 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Complete blood count
Description: Study haemtological disturbances in neonates with necrotizing enterocolities
Study NCT06632041 — intervention group
Intervention type: OTHER
Intervention: Complete blood count
Description: Haemtological disturbances in neonates with necrotizing enterocolities
Study NCT05950802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Higher dose than traditional conditioning chemo
Study NCT05950802 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: TLI
Description: radiation given with conditioning chemo
Study NCT05020860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 80 mg/m2 IV administered on Days 1, 8, 15 of each 21-day cycle
Study NCT05020860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin AUC 1.5 IV administered on Days 1, 8, 15 of each 21-day cycle
Study NCT05020860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab 8 mg/kg loading dose, followed by 6 mg/kg maintenance dose, administered on Day 1 of each 21-day cycle
Study NCT05020860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: Pertuzumab 840 mg loading dose, followed by 420 mg maintenance dose, administered on Day 1 of each 21-day cycle
Study NCT05020860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: 60 mg/m2 IV administered on Day 1 of each 14-day cycle
Study NCT05020860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 600 mg/m2 IV administered on Day 1 of each 14-day cycle
Study NCT05020860 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Either 200 mg IV administered on Day 1 of Cycles 1-4, or 400 mg IV administered on Day 1 of Cycles 1 and 3 of the paclitaxel/carboplatin regimen.~400 mg on Day 1 of Cycles 1 and 4 of the dose-dense AC regimen.
Study NCT04824547 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: All exercises programs will applied two sessions per week, totally eight week..
Study NCT06069492 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wheat-containing food
Description: One daily serving of 38 grams wheat-containing pasta contains either 5000 mg wheat protein (standard-dose group) or 650 mg wheat protein and 4350 gluten-free flour (low-dose group)